Journal
NATURE REVIEWS CANCER
Volume 15, Issue 3, Pages 152-165Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3895
Keywords
-
Categories
Funding
- US National Institutes of Health [CA183252, DK092883]
- Sam Waxman Cancer Research Foundation
- Edward P. Evans Foundation
Ask authors/readers for more resources
DNA methylation patterns are disrupted in various malignancies, suggesting a role in the development of cancer, but genetic aberrations directly linking the DNA methylation machinery to malignancies were rarely observed, so this association remained largely correlative. Recently, however, mutations in the gene encoding DNA methyltransferase 3A (DNMT3A) were reported in patients with acute myeloid leukaemia (AML), and subsequently in patients with various other haematological malignancies, pointing to DNMT3A as a critically important new tumour suppressor. Here, we review the clinical findings related to DNMT3A, tie these data to insights from basic science studies conducted over the past 20 years and present a roadmap for future research that should advance the agenda for new therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available